Uwe A. Wittel

Lipotoxic fingerprints in clinically relevant postoperative pancreatic fistula: fatty acid–driven cytotoxicity targets cells involved in anastomotic healing

Self-reported financial difficulties of colorectal cancer patients 1 year after start of treatment.

The distance to arteries predicts the oncological outcome in pancreatic cancer surgery – results from a 3D reconstruction model

Separation of small extracellular vesicles (sEV) from human blood by Superose 6 size exclusion chromatography

Thoracic Epidural Analgesia Is Not Associated With Improved Survival After Pancreatic Surgery: Long-Term Follow-Up of the Randomized Controlled PAKMAN Trial

Integrated Analysis of Cell-Free DNA and Novel Protein Biomarkers for Stratification and Therapy Monitoring in Stage IV Pancreatic Cancer: A Preliminary Study.

Integrated Analysis of Cell-Free DNA and Novel Protein Biomarkers for Stratification and Therapy Monitoring in Stage IV Pancreatic Cancer: A Preliminary Study

Integrated Analysis of Cell-Free DNA and Novel Protein Biomarkers for Stratification and Therapy Monitoring in Stage IV Pancreatic Cancer

BRAF ^Δβ3-αC in-frame deletion mutants differ in their dimerization propensity, HSP90 dependence, and druggability

BRAF^Δβ3-αC in-frame deletion mutants differ in their dimerization propensity, HSP90 dependence, and druggability.

Clinical characteristics and long-term outcomes following pancreatic injury - An international multicenter cohort study.

Open-label, single arm phase II trial investigating the efficacy, safety and quality of life of neoadjuvant chemotherapy with liposomal irinotecan combined with oxaliplatin and 5-fluorouracil/folinic acid followed by curative surgical resection in patients with hepatic oligometastatic adenocarcinoma of the pancreas (HOLIPANC).

Perioperative or only adjuvant gemcitabine plus nab-paclitaxel for resectable pancreatic cancer (NEONAX)—a randomized phase II trial of the AIO pancreatic cancer group

Randomized phase III trial of induction chemotherapy followed by chemoradiotherapy or chemotherapy alone for nonresectable locally advanced pancreatic cancer: First results of the CONKO-007 trial.

Biomarkers in Liquid Biopsies for Prediction of Early Liver Metastases in Pancreatic Cancer.

Rapid Capture of Cancer Extracellular Vesicles by Lipid Patch Microarrays

Longitudinal analysis of cell-free mutated KRAS and CA 19–9 predicts survival following curative resection of pancreatic cancer

Perioperative cell-free mutant <i>KRAS</i> dynamics in patients with pancreatic cancer

Perioperative cell-free mutant KRAS dynamics in patients with pancreatic cancer.

Development and Clinical Validation of Discriminatory Multitarget Digital Droplet PCR Assays for the Detection of Hot Spot KRAS and NRAS Mutations in Cell-Free DNA

Metabolic Profiling of Early and Late Recurrent Pancreatic Ductal Adenocarcinoma Using Patient-Derived Organoid Cultures.

Metabolic Adaptation during nab-Paclitaxel Resistance in Pancreatic Cancer Cell Lines.

Clinical course and pancreas parenchyma sparing surgical treatment of severe pancreatic trauma

Pancreatic Resection in Older Patients: A Retrospective Single-Center Outcome Analysis

Consensus in determining the resectability of locally progressed pancreatic ductal adenocarcinoma - results of the Conko-007 multicenter trial.

Management and outcomes of intraductal papillary mucinous neoplasms.

Retroperitoneal soft tissue sarcoma: low-dose neoadjuvant radiation therapy followed by surgery with or without intraoperative radiotherapy and adjuvant radiation therapy

Is Moxifloxacin a Treatment Option for Pancreatic Infections? A Pharmacometric Analysis of Serum and Pancreatic Juice.

Identification and Validation of a Diagnostic and Prognostic Multi-Gene Biomarker Panel for Pancreatic Ductal Adenocarcinoma

Minimally Invasive versus Open Distal Pancreatectomy for Ductal Adenocarcinoma (DIPLOMA)